80.   South Africa would like to recall its previous interventions on the substantive items that constitute the triplets. Specifically, on the issues of the relationship between the TRIPS Agreement and the CBD, we recall Paragraph 19 of the Doha Declaration. Document TN/C/W/59 constitutes an approach that a large number of developing countries have supported. This document requires access and benefit sharing, prior informed consent and disclosure of the source of material when a patent is applied for. South Africa is a Contracting Party to the CBD and has ratified the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization. 81.   The issue of unauthorised use of biological resources and traditional knowledge remains a serious problem internationally. The failure to ask permission or acknowledge the origin or source of the invention or creativity, failure to share benefits, culturally offensive use, and grant of patents or other forms of IP rights in error remain unaddressed. Given the international dimension of bioprospecting and patenting activities, national legislation is insufficient to address misappropriation and misuse of genetic resources and traditional knowledge. Strong multilateral disciplines are required in this area. Given the continued impasses in the WIPO IGC, the most appropriate forum to address these issues would be the WTO. 82.   In respect of procedural issues, this delegation once again calls on the Secretariat to update the three factual notes contained in documents IP/C/W/368/Rev.1, IP/C/W/369/Rev.1 and IP/C/W/370/Rev.1. We believe that an update of these documents will stimulate a debate that is characterized by persistent restatement of long held positions. We further support a briefing by the CBD Secretariat on the Nagoya Protocol and subsequent developments.